获取组织用于晚期肺癌诊断和全面的生物标志物测试：国家肺癌圆桌会议最佳实践指南。
Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.
发表日期：2023 Mar 01
作者：
Adam H Fox, Mizuki Nishino, Raymond U Osarogiagbon, M Patricia Rivera, Lauren S Rosenthal, Robert A Smith, Farhood Farjah, Lynette M Sholl, Gerard A Silvestri, Bruce E Johnson
来源：
Best Pract Res Cl Ob
摘要：
肺癌非小细胞肺癌（NSCLC）生物标记驱动治疗的进展为改善患者的治疗（及其结果）提供了机会，同时也为公平的医疗服务提出了新的挑战。在过去的十年间，新的生物标记驱动治疗不断发展，其使用的不断发展的指示增加了跨学科沟通和协调对于患有或疑似患有肺癌的患者的重要性。多学科团队面临着完成全面和及时的生物标志物测试以及应对复杂而又迫切的疾病不断变化的证据的挑战。这个指南为NSCLC全面生物标志物测试的当前状态提供背景，审查生物标志物测试如何与患者的诊断过程相结合，并利用一系列案例场景详细描述影响生物标志物测试成功和及时性的最佳实践和常见缺陷。
© 2023 The Authors. CA：Cancer Journal for Clinicians，由Wiley Periodicals LLC代表美国癌症协会出版。
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.© 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.